ABC | Volume 114, Nº1, Janeiro 2020

Artigo de Revisão Fernandes et al. Insuficiência cardíaca com fração ejeção preservada Arq Bras Cardiol. 2020; 114(1):120-129 16. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, KamkeW, et al. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. JAMA . 2013;309(8):781-91. 17. Pitt B, Pfeffer M, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med . 2014;370(15):1383-92. 18. Yancy CW, Jessup M, Levine GN, Halperin JL. 2017 ACC / AHA / HFSA Focused Update of the 2013 ACCF / AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.. J Am Coll Cardiol. 2017;70(6):776-803. 19. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet . 2012;380(9851):1387-95. 20. SolomonSD,RizkalaAR,GongJ,MangW,AnandIS,GeJ,etal.AngiotensinReceptor NeprilysinInhibitioninHeartFailureWithPreservedEjectionFractionRationaleand DesignofthePARAGON-HFTrial. JACCHeartFail .2017;5(7):471-82. 21. Komajda M, Isnard R, Cohen-solal A, Metra M, Pieske B, Ponikowski P, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial ivabradine studY (EDIFY). Eur J Heart Fail. 2017;19(11):1495-503. 22. KosmalaW, HollandDJ, Rojek, Wright L, Przewlocha-KosmalaM, Marwick TH. Effect of If -Channel Inhibition on Hemodynamic Status and Exercise. 23. Ahmed A, RichMW, Fleg JL, ZileMR, Young JB, KitzmanDW, et al. Effects of Digoxin onMorbidity andMortality inDiastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial. Circulation. 2006;114(5):397-403. 24. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al. IsosorbideMononitrate inHeart Failurewith Preserved Ejection Fraction. N Engl J Med. 2015;373(24):2314-24. 25. Zamani P, Rawat D, Shiva-Kumar O, Geraci S, Bhuva R, Konda P, et al. The Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure with Preserved Ejection Fraction. Circulation . 2015;131(4):371-80. 26. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. JAMA. 2013;309(12):1268-77. 27. Bonderman D, Prestch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, et al. Acute Hemodynamic Effects of Riociguat in Patients With PulmonaryHypertensionAssociatedWithDiastolicHeart Failure (DILATE-1) A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study. Chest. 2014;146(5):1274-85. 28. Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, et al. Vericiguat in patients withworsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119-27. 29. Maier L, Layug BL, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the Treatment of Diastolic Heart Failure in Patients With Preserved Ejection Fraction. JACC Hear Fail. 2013;1(2):22-115. 30. Reddy YNV, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA. The B-adrenergicagonistAlbuterolImprovesPulmonaryVascularReserve inHeart Failure with Preserved Ejection Fraction. Circ Res. 2019;124(2):306-14. 31. Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre ,open-label, single-arm, phase 1 trial. Lancet. 2016;387(10025):1298-304. 32. KayeDM, HasenfußG, Neuzil P, Post MC, Doughty R, Trochu JN, et al. One- Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for theManagement of Heart FailureWith Preserved Ejection Fraction. Circ Heart Fail. 2016 Dec;9(12). pii: e003662. 33. FeldmanT,MauriL,KahwashR,LitwinS,RicciardiMJ,VanderHarstP,etal.A Transcatheter InterAtrialShuntDevice fortheTreatmentofHeartFailurewith Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial. Circulation. 2018;137(4):364-75. 34. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658-66. 35. Adamson PB, AbrahamWT, Bourge RC, CostanzoMR, Hasan A, Yadav C, et al. Wireless Pulmonary Artery Pressure Monitoring Guides Management to ReduceDecompensation inHeart FailureWith Preserved Ejection Fraction. Circ Heart Fail. 2014;7(6):935-44. 36. Edelmann F, Gelbrich G, Düngen H, Frohling S, Wachter R, Stahrenberg R, et al. Exercise Training Improves Exercise Capacity andDiastolic Function in Patients With Heart FailureWith Preserved Ejection Fraction: Results of the Ex-DHF (Exercise training in Diastolic Heart Failure) Pilot Study. J Am Coll Cardiol. 2011;58(17):1780-91. 37. Kitzman DW. Exercise Training in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2011;58(17):1792-4. 38. FuM,ZhouJ,ThunströmE,AlmgrenT,GroteL,Bollano,Eetal.Optimizingthe ManagementofHeartFailurewithPreservedEjectionFraction intheElderlyby TargetingComorbidities(OPTIMIZE-HFPEF).JCardFail.2016;22(7):539-44. 39. Borlaug B. Rate-Adaptive Atrial Pacing In Diastolic Heart Failure (RAPID- HF) [Internet]. Rochester, Minnesota: Mayo Clinic; 2014 Abril 7 [Last Update 2019 May 14]. Available from: https://clinicaltrials.gov/ct2/show/ NCT02145351. 40. Doehner W. Effect of IV Iron (Ferric Carboxymaltose, Ferinject) on Exercise Tolerance, Symptoms andQuality of Life in PatientsWithHeart FailureWith Preserved Ejection Fraction (HFpEF) and IronDeficiencyWith andWithout Anaemia [Internet]. Berlin, Germany: Charite University; 2017 August 1 [Last Update 2017 August 24]. Available from: https://clinicaltrials.gov/ct2/ show/NCT03074591. 41. Seferivic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853-72. 42. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, andMortality in Type 2Diabetes. N Engl J Med. 2015;373(22):2117-28. 43. Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. 44. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahnet A, al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57. 45. Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács A, Christian S, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690-700. 46. Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, et al. EMPERIAL Investigators and National Coordinators. Rationale and design of the EMPERIAL Preserved and EMPERIAL Reduced trials of empagliflozin in patients with chronic heart failure. Eur Heart Fail. 2019;21(7):932-42 47. Kosiborod M. Effects of Dapagliflozin on Biomarkers,Symptoms and Functional Status in patients with PRESERVED Ejection Fraction Heart Failure. [Internet]. [Cited in 2017 March 01]. Available from: https:// clinicaltrials.gov/ct2/show/NCT03030235. 48. A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) [Internet].2017 March 2 [Last Update 2019 August 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03057951. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 129